Previously submitted to: JMIR Diabetes (no longer under consideration since Sep 29, 2021)
Date Submitted: May 18, 2021
Open Peer Review Period: May 18, 2021 - Jul 13, 2021
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Use of a Diabetes Self-Management App in Combination with a 4mm Pen Needle and its Impact on Glycemic Variability and Patient Reported Outcomes in People with Type 2 Diabetes Using Basal-Bolus Insulin Therapy
ABSTRACT
Background:
Studies of mobile diabetes applications (apps) have demonstrated improvements in glycemia, and patient reported outcomes (PROs). In addition, the potential for reduced glycemic variability has been realized through the use of shorter pen needles (PN) and adoption of proper injection techniques.
Objective:
To determine the impact of using a diabetes mobile app plus a novel 4 mm pen needle (PN) on patient reported outcomes (PROs) and glycemic outcomes in people with T2DM using multiple daily injections (MDI) of insulin.
Methods:
This was a prospective, parallel group, randomized controlled trial. People with T2DM administering MDI with baseline hemoglobin A1c (HbA1c) concentrations of 8% - 11% were enrolled. The study lasted 10 weeks with PRO’s answered Pre/Post. Subjects wore a blinded flash glucose monitor (fGM) the first two and last two weeks. Following fGM use, subjects were randomized 1:1 to either Intervention (BD Diabetes Care (DC) App + BD Nano 2nd Gen PN) or Control for 8 weeks. Controls used their current PN and did not use diabetes apps. At study end, the Intervention group answered a survey on satisfaction with the app and PN.
Results:
Fifty-eight subjects were randomized and 57 completed the study (Intervention n=27, Control n=30). Mean (SD) age of subjects was 53.8 ± 10.3 (mean ± SD) years and duration of insulin therapy was 9.5 ± 6.5 years. At study end, there were no significant differences in PROs between groups, except an improvement in medication adherence (ARMS-D) in Controls, leading to significant between-group differences (P = 0.04). From fGM data, there were no significant differences in most glycemic measures between groups except for a trend for improved glycemic variability as measured by the mean amplitude of glycemic excursions (MAGE) in the Intervention group (P = 0.06). Controls spent significantly less time in hypoglycemia but had a 2 to 3-fold higher incidence at baseline. Intervention subjects had numerical improvements in several glycemic parameters whereas Controls had numerical decrements in these values over the study. In general, Intervention subjects reported satisfaction with the app and PN.
Conclusions:
This is the first BD DC App study, in combination with BD Nano 2nd Gen PN, to assess glycemic outcomes. The Intervention showed a trend for improved glycemic variability and numerical improvements in several glycemic measures over the course of the study. This combination intervention shows promising results for reduced glycemic variability and the potential to positively impact patients’ diabetes self-management. Clinical Trial: ClinicalTrials.gov Identifier: NCT04090242
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.